Generic versions of Valcyte and Activella hit the US market
Ireland-domiciled pain drugmaker Endo International (Nasdaq: ENDP) says that its Qualitest subsidiary has launched a generic version of Swiss pharma major Roche (ROG: SIX) Valcyte (valganciclovir) tablets USP, 450mg.
"We are pleased to announce the commercial availability of generic Valcyte," said Rajiv De Silva, president and chief executive of Endo, adding: "Our generic product, as the first generic version of Valcyte available in the USA plays an important role in providing patients with a more affordable treatment option."
For the 12 months ending September 30, 2014, Valcyte, for the treatment of cytomegalovirus (CMV) retinitis (eye infection), had total US sales of around $440 million, according to IMS Health data quoted by Endo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze